Cyfuse Biomedical K.K.

Company Snapshot

Founded: 2010
Entity Type: Public
Region: Japan
Headquarter: Tokyo, Japan
Key Geographics: Asia-Pacific
Corporate Address: South Tower-1F. Sumitomo Fudosan Tokyo Mita, 3-5-27, Mita Minato-ku, Tokyo 108-6301, Japan Tel. +81-3-6435-1885 www.en.cyfusebio.com

Company Overview

The Japanese bioprinting company comes from the term “fusing cells (cyto-).” The company generates tissues and organs by fusing cells through fusion activities in a variety of different aspects. Cyfuse’s specialty is a tissue fabrication process that doesn’t need any scaffold, such as polymers or collagen, to enable faster and more efficient tissue generation.

Cyfuse Biomedical K.K. In Reports

Bioprinting: Technologies and Global Markets

Global bioprinting technologies market should reach $5.0 billion by 2027 from $2.4 billion in 2022 at a CAGR of 16.2% for the forecast period of 2022-27.

3D Printed Medical Devices

BCC Research Market Report for 3D printed medical devices should grow from $1.7 billion in 2021 to $4.9 billion by 2026, at compound annual growth rate (CAGR) of 24.5%

3D Printed Medical Devices

Explore the global 3D printing of medical device market along with characterisation & quantification of orthopedic, prosthetic & cranial implants, & surgical instruments.

Company's Business Segments

  • Regenerative Medicines : The company researched, developed, and commercialized tissue fabrication systems and cell-based products through its 3D tissue-engineering technology.

Applications/End User Industries

  • Healthcare
  • Pharmaceuticals
  • Tissue Engineering
  • Medicines
AI Sentiment